These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 17659480)
1. Advances in gamma-secretase modulation. Pissarnitski D Curr Opin Drug Discov Devel; 2007 Jul; 10(4):392-402. PubMed ID: 17659480 [TBL] [Abstract][Full Text] [Related]
2. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883 [TBL] [Abstract][Full Text] [Related]
3. Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds. Czirr E; Weggen S Neurodegener Dis; 2006; 3(4-5):298-304. PubMed ID: 17047371 [TBL] [Abstract][Full Text] [Related]
4. The structure and function of Alzheimer's gamma secretase enzyme complex. Krishnaswamy S; Verdile G; Groth D; Kanyenda L; Martins RN Crit Rev Clin Lab Sci; 2009; 46(5-6):282-301. PubMed ID: 19958215 [TBL] [Abstract][Full Text] [Related]
5. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment. Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227 [TBL] [Abstract][Full Text] [Related]
6. Secretase inhibitors and modulators for Alzheimer's disease treatment. Tomita T Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777 [TBL] [Abstract][Full Text] [Related]
7. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease. D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891 [TBL] [Abstract][Full Text] [Related]
8. An improved cell-based method for determining the γ-secretase enzyme activity against both Notch and APP substrates. McKee TD; Loureiro RM; Dumin JA; Zarayskiy V; Tate B J Neurosci Methods; 2013 Feb; 213(1):14-21. PubMed ID: 23219895 [TBL] [Abstract][Full Text] [Related]
9. Development and mechanism of γ-secretase modulators for Alzheimer's disease. Crump CJ; Johnson DS; Li YM Biochemistry; 2013 May; 52(19):3197-216. PubMed ID: 23614767 [TBL] [Abstract][Full Text] [Related]
10. Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta. Bakshi P; Jin C; Broutin P; Berhane B; Reed J; Mullan M Bioorg Med Chem; 2009 Dec; 17(23):8102-12. PubMed ID: 19853461 [TBL] [Abstract][Full Text] [Related]
11. [Therapy of Alzheimer disease]. Kovács T Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816 [TBL] [Abstract][Full Text] [Related]
12. γ-Secretase modulator in Alzheimer's disease: shifting the end. Xia W; Wong ST; Hanlon E; Morin P J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916 [TBL] [Abstract][Full Text] [Related]